Research progress of tenecteplase in acute ischemic stroke
10.3969/j.issn.1672-5921.2025.02.009
- VernacularTitle:替奈普酶治疗急性缺血性卒中的研究进展
- Author:
Na ZHUO
1
;
Yu FAN
1
;
Meili ZHAO
1
;
Lu WANG
1
;
Julin ZHANG
1
Author Information
1. 014040 内蒙古医科大学包头临床学院包头市中心医院神经内科
- Publication Type:Journal Article
- Keywords:
Tenecteplase;
Ischemic stroke;
Bridging therapy;
Intravenous thrombolysis;
Review
- From:
Chinese Journal of Cerebrovascular Diseases
2025;22(2):127-134
- CountryChina
- Language:Chinese
-
Abstract:
Tenecteplase is a third-generation thrombolytic drug.Compared with alteplase,it has the advantages of longer half-life and higher fibrin specificity.The effectiveness and safety of tenecteplase in the treatment of acute ischemic stroke have been extensively studied in clinical research.The article summarized the research progress of tenecteplase in the treatment of acute ischemic stroke based on completed randomized controlled studies and related Meta-analyses,and explored the pharmacological characteristics,effectiveness,and safety of tenecteplase,as well as current guideline recommendations,aiming to offer a reference for choosing more appropriate diagnostic and therapeutic methods for patients with acute ischemic stroke.
